Merck & Co에 대한 매도 수량은 투자자에게 Merck & Co의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Merck & Co (NYSE:MRK) 주식, 공매도 수량 보고

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Biotech

Health Care

Technicals

Signals

Trading Ideas

General

GILD

머크 앤드 컴퍼니(NYSE:MRK)와 길리어드 사이언스(NYSE:GILD)는 주가가 상당히 다른 양상을 보이는 두 제약 대기업이다. 뉴저지주 라웨이에 본사를 둔 머크는 방금 데스 크로스(Death Cross)를 표시하여 앞으로 발생할 수 있는 문제를 예고했다. 반면 캘리포니아주 포스터 시티에 본사를 둔 길리어드는 강세 모멘텀의 신호인 골든 크로스(Golden Cross)를 보여주고 있다.

머크의 데스 크로스 vs 길리어드의 골든 크로스: 서로 다른 양상을 보이는 두 제약 기업

News

Movers

CRWD

New Oriental Education & Technology Group

ENTG

INTC

MBLY

MRNA

MSTR

PINS

SNAP

TEAM

이들 12개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 심보틱(NASDAQ:SYM)의 주가는 예상보다 나쁜 3분기 실적에 따라 지난주 39.23% 하락했고, 4분기 매출 전망도 부진했다. 

마이크로스트레티지 및 인텔은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 28일-8월 3일)

Equities

Large Cap

Sector ETFs

Small Cap

Global

Exclusives

Tech

ETFs

ABBV

ALNY

AMGN

HRTS

테마(Tema) ETFs의 설립자이자 CEO인 마우리츠 팟(Maurits Pot)은 비만 치료를 위한 GLP-1 약물 시장은 1조 달러 이상으로 급등할 것으로 예상된다고 벤징가(Benzinga)와의 독점 인터뷰에서 그의 낙관적인 예측을 공유했다. 

단독: GLP-1 체중 감량 약물은 수조 달러 규모의 시장 가능성, 테마 ETFs CEO의 전망

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

MERCK & CO ORD

Thermo Fisher Scientific&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) one of the largest contract drug manufacturing sites in the U.S., has repeatedly been flagged for regulatory violations.
Thermo Fisher&#8217;s Greenville facility manufactures around 40 medicines, including Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) weight-loss <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35142181/weight-loss-drug-boom-has-another-ripple-effect-rapid-growth-expected-in-fill-finish-market" rel="noreferrer noopener">drug Wegovy (semaglutide)</a>.
Recently, Stephen&#8217;s analyst said that Thermo Fisher&#8217;s pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand and biologics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular" rel="noreferrer noopener">drug substance production</a>.
Over the past decade, the Greenville plant has been cited for issues related to contamination prevention, including two incidents earlier this year, Reuters noted, citing FDA documents.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook</a>.
Despite these concerns, the FDA did not take regulatory action, stating that the issues had been resolved to its satisfaction and that there was no evidence that patients had been harmed as a result.
During a recent inspection in May, the FDA identified manufacturing problems with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Beyfortus. The respiratory syncytial virus (RSV) preventive drug for infants and toddlers scored <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33262341/astrazeneca-sanofis-respiratory-syncytial-virus-treatment-scores-fda-approval-to-prevent-infectio" rel="noreferrer noopener">FDA approval in 2023</a>.
The Reuters report highlighted that the FDA identified 17 deficiencies during the Beyfortus audit, including insufficient visual inspections for particulate matter in injectable drugs and issues with staff handling of sterile components.
The agency noted that Thermo Fisher&#8217;s equipment sterilization procedures were inadequate, and visual inspections for injectable drug contaminants failed.
Thermo Fisher has since addressed these issues, providing the FDA with the necessary data on drug safety, including control over bubble size in injectable medications. However, experts remain concerned about the plant&#8217;s approach to quality control.
In July, Merck &amp; Co Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Phase 2b/3 trial (MK-1654-004) of&nbsp;clesrovimab (MK-1654) to protect infants from respiratory syncytial virus (RSV) disease met its primary safety <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39916077/merck-competes-with-sanofiastrazeneca-as-its-rsv-treatment-drug-meets-primary-goal-in-late-stage-" rel="noreferrer noopener">and efficacy endpoints</a>.
Price Action: TMO stock is down 0.39% at $598.59 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling" target="_blank" rel="noreferrer noopener">Rivian&#8217;s Production Forecast Hits Bump, Supply Shortage Sends Shares Tumbling</a></li>
</ul>
Photo via Shutterstock

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses

Across the recent three months, 8 analysts have shared their insights on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, a high estimate of $155.00, and a low estimate of $125.00. Observing a downward trend, the current average is 2.29% lower than the prior average price target of $147.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727985619_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Merck &amp; Co by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$134.00</td>
<td>$132.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merck &amp; Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Merck &amp; Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merck &amp; Co analyst ratings.</a>
<h2>About Merck &amp; Co</h2>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Financial Milestones: Merck &amp; Co's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merck &amp; Co's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 7.16%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Merck &amp; Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 13.0%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Merck &amp; Co's ROA excels beyond industry benchmarks, reaching 4.99%. This signifies efficient management of assets and strong financial health.
Debt Management: Merck &amp; Co's debt-to-equity ratio is below the industry average at 0.87, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Merck & Co: Insights From 8 Analyst Reviews

Cantor Fitzgerald analyst Louise Chen reiterates Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Overweight and maintains $155 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target

In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Merck &amp; Co Background</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck &amp; Co Inc</td>
<td>20.76</td>
<td>6.52</td>
<td>4.57</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>109.74</td>
<td>59.16</td>
<td>20.69</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>38.70</td>
<td>30.74</td>
<td>13.49</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.38</td>
<td>5.42</td>
<td>4.58</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>38.63</td>
<td>6.24</td>
<td>5.06</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.41</td>
<td>5.55</td>
<td>4.83</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>29.98</td>
<td>1.74</td>
<td>2.67</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.74</td>
<td>17.56</td>
<td>9.91</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.07</td>
<td>4.19</td>
<td>1.70</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>43.32</td>
<td>0.83</td>
<td>1.46</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.89</td>
<td>3.75</td>
<td>3.83</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.59</td>
<td>1.80</td>
<td>1.97</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>40.58</td>
<td>8.04</td>
<td>8.92</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.79</td>
<td>33.22</td>
<td>0.75</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.11</td>
<td>2.06</td>
<td>3.16</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>32.85</td>
<td>12.88</td>
<td>5.93</td>
<td>21.87%</td>
<td>$33.82</td>
<td>$70.57</td>
<td>13.06%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining Merck &amp; Co, the following trends can be inferred: 
<ul>
<li>
A Price to Earnings ratio of 20.76 significantly below the industry average by 0.63x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
The current Price to Book ratio of 6.52, which is 0.51x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
With a relatively low Price to Sales ratio of 4.57, which is 0.77x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The Return on Equity (ROE) of 13.0% is 8.87% below the industry average, suggesting potential inefficiency in utilizing equity to generate profits.
</li>
<li>
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.45 Billion, which is 0.22x below the industry average, the company may face lower profitability or financial challenges.
</li>
<li>
The gross profit of $12.37 Billion is 0.18x below that of its industry, suggesting potential lower revenue after accounting for production costs.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 7.16% compared to the industry average of 13.06%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727967642_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is a financial metric that helps determine the level of financial risk associated with a company's capital structure.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Merck &amp; Co against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
In terms of the debt-to-equity ratio, Merck &amp; Co has a lower level of debt compared to its top 4 peers, indicating a stronger financial position.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity with a lower debt-to-equity ratio of 0.87.
</li>
</ul>
<h3>Key Takeaways</h3>
For Merck &amp; Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may indicate a need for further analysis to understand the company's financial health and competitive position within the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals

Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) made a promise&nbsp;to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) in turning to oncology for its next growth story. Both Moderna and Pfizer made history during the COVID-19 pandemic thanks to mRNA technology. Now, Moderna and Pfizer embarked on a journey to treat cancer with mRNA science. By using mRNA-based next-generation CRC screening tests, a much smaller and less known pharma player,&nbsp;Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>), is already redefining standards in early cancer detection with its flagship colorectal cancer test ColoAlert, while also tackling cancer prevention.
<h3>Moderna Has Several Oncology Trials In Motion</h3>
First, there is the collaboration with Merck &amp;Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>). The combination of&nbsp;immunotherapy blockbuster drug Keytruda from Merck and the&nbsp;experimental mRNA vaccine showed encouraging results in patients diagnosed with melanoma, a deadly form of skin cancer. During summer, Merck and Moderna released positive mid-stage results that showed improved survival rates and showed long-lasting efficacy. Along with targeting melanoma by joining forces with Merck, Moderna is also conducting clinical trials of a cancer treatment for adults diagnosed with solid tumor cancers, lymphoma and non-small lung cancer.&nbsp;&nbsp;
<h3>Mainz Biomed Is Gearing Up To Revolutionize Early Cancer Detection</h3>
Determined to lead the way in cancer diagnostics, Mainz Biomed opened the week by releasing a statement to shareholders that highlighted its strategic plans,&nbsp;clinical developments, and its upcoming FDA trial anticipated for 2025 which should pave the way for entry into the U.S. market.&nbsp;With its innovative diagnostic solution ColoAlert that is already marketed across Europe, Mainz&nbsp;Biomed&nbsp;has positioned itself for substantial growth in global markets next year.&nbsp;With its&nbsp;flagship non-invasive test that not only revolutionized early detection of colorectal cancer but also prevention by identifying precancerous lesions, particularly advanced adenomas, Mainz Biomed reported significant clinical success in both US and European trials. Identifying these lesions allows for timely intervention through colonoscopy and adenoma removal, thereby warding off cancer from developing in the first place.
In addition to its mRNA next generation CRC screening test,&nbsp;Mainz&nbsp;Biomed&nbsp;is also developing PancAlert for an easy and convenient at home test for pancreatic cancer.
Tackling A&nbsp;fight that modern medicine just cannot seem to win.
Despite its efforts to translate scientific research into effective medicines for cancer patients, Pfizer is still not near a breakthrough in oncology. Undoubtably, Pfizer is betting big on oncology to turn its ship around, which it showed with the&nbsp;$43 billion acquisition of the cancer drugmaker Seagen. With the combined pipeline,&nbsp;Pfizer is hoping to produce at least eight blockbuster medicines by the end of the decade. But this is still only a promise while&nbsp;cancer remains one of the most complex diseases of the modern civilization and one of science&rsquo;s biggest challenges. Only time will show if mRNA technology is the missing piece of the puzzle for science to finally win the cancer battle. While no one knows if the COVID-19 success of mRNA science&nbsp;can be replicated for cancer, it does seem it is a good enough of a tool to make some much needed breakthroughs.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Penny Stocks

MYNZ

The Covid Era Tech Promises To Reinvent Cancer Treatment

Merck (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session&#39;s end. This change lagged the S&amp;P 500&#39;s daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%.
The pharmaceutical company&#39;s shares have seen a decrease of 2.27% over the last month, aligning with the Medical sector and falling behind the S&amp;P 500&#39;s gain of 1.71%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 31, 2024. The company is forecasted to report an EPS of $1.77, showcasing a 16.9% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.48 billion, up 3.24% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $8.01 per share and a revenue of $64.14 billion, demonstrating changes of +430.46% and +6.69%, respectively, from the preceding year.
It&#39;s also important for investors to be aware of any recent modifications to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company&#39;s business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Merck possesses a Zacks Rank of #4 (Sell).
Looking at its valuation, Merck is holding a Forward P/E ratio of 14.33. This valuation marks a discount compared to its industry&#39;s average Forward P/E of 15.78.
We can additionally observe that MRK currently boasts a PEG ratio of 1.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company&#39;s projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.67.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 44, this industry ranks in the top 18% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
<a href="https://www.zacks.com/stock/news/2342265/merck-mrk-stock-sinks-as-market-gains-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-2342265">To read this article on Zacks.com click here.</a>

Earnings

Merck Stock Sinks As Market Gains: Here's Why

Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) inked an option and licensing deal with Merck &amp; Co., Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for two <a href="https://www.benzinga.com/pressreleases/24/09/g41043464/evaxion-significantly-expands-vaccine-development-collaboration-with-msd" target="_blank" rel="noreferrer noopener">preclinical vaccine candidates</a>.
Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 and EVX-B3.
EVX-B2 is a protein-based candidate for Gonorrhea, and EVX-B3 targets an undisclosed infectious agent.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36765592/why-is-cancer-therapy-focused-evaxion-biotech-stock-trading-higher-today" rel="noreferrer noopener">Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?</a>
Evaxion will receive an upfront payment of $3.2 million and up to $10 million in 2025 as part of the deal. The agreement is contingent upon Merck exercising its option to license either one or both candidates.
In addition, Evaxion is eligible for development, regulatory, and sales milestone payments with a potential value of up to $592 million per product, and royalties on net sales.
Christian Kanstrup, CEO of Evaxion, called the collaboration &#8220;transformative&#8221; and a &#8220;strong validation&#8221; of the company&#8217;s AI-Immunology platform and vaccine candidates. 
Evaxion and Merck have been collaborating on EVX-B3 since 2023. At the time, Merck, through its Global Health Innovation Fund (MGHIF), led a private placement round of financing for Evaxion to become the company&#8217;s single largest shareholder.
MGHIF also participated in Evaxion&#8217;s public offering in February this year.
Last year, Evaxion Biotech collaborated with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion&#8217;s EDEN-<a href="https://www.benzinga.com/general/biotech/23/09/34768492/why-is-cancer-immunotherapy-focused-evaxion-biotech-stock-trading-higher-today" target="_blank" rel="noreferrer noopener">discovered gonorrhea targets</a>.
Price Action: EVAX stock is up 8.83% at $3.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41044267/exclusive-srivarus-prana-2-0-electric-motorcycle-earns-key-indian-certification" target="_blank" rel="noreferrer noopener">EXCLUSIVE: SRIVARU&#8217;s PRANA 2.0 Electric Motorcycle Earns Key Indian Certification</a></li>
</ul>
Image: Courtesy of Merck

Contracts

EVAX

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Under the terms of the agreement, Evaxion has granted MSD an option to exclusively license Evaxion's preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea and EVX-B3 targets an undisclosed infectious agent.

Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product

Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress

Financial giants have made a conspicuous bullish move on Merck &amp; Co. Our analysis of options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $119,340, and 5 were calls, valued at $224,086.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $120.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 2075.86, with a total volume reaching 6,696.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $100.0 to $120.0, throughout the last 30 days.
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727297131_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.0</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$120.00</td>
<td>$58.1K</td>
<td>1.2K</td>
<td>60</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$24.5</td>
<td>$20.0</td>
<td>$21.9</td>
<td>$100.00</td>
<td>$56.9K</td>
<td>318</td>
<td>26</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.99</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$118.00</td>
<td>$44.4K</td>
<td>972</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.9</td>
<td>$0.88</td>
<td>$0.9</td>
<td>$118.00</td>
<td>$36.9K</td>
<td>972</td>
<td>2.8K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.35</td>
<td>$3.2</td>
<td>$3.35</td>
<td>$118.00</td>
<td>$34.8K</td>
<td>16</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
After a thorough review of the options trading surrounding Merck &amp; Co, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>With a volume of 7,899,351, the price of MRK is down -0.1% at $114.84. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What Analysts Are Saying About Merck &amp; Co</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $155.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $155. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On Merck & Co

On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and esophageal <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">squamous cell carcinoma</a>.
The FDA <a target="_blank" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024" rel="noreferrer noopener">notes</a> that the current labeling for approved checkpoint inhibitors in this indication reflects broad approvals in the intent to treat patient populations agnostic of programmed death cell ligand-1 (PD-L1) expression.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer</a>.
Cumulative data has shown that PD-L1 expression appears to be a predictive biomarker of treatment efficacy in this patient population; however, clinical trials have used different approaches to assess PD-L1 expression and different thresholds to define PD-L1 positivity.
The review includes existing approvals for&nbsp;Bristol Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Opdivo (nivolumab) and Yervoy (ipilimumab),&nbsp;Merck &amp; Co Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)&nbsp;Keytruda (pembrolizumab), and pending applications for&nbsp;BeiGene Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)&nbsp;Tevimbra (tislelizumab).
In a&nbsp;<a target="_blank" href="https://www.fda.gov/media/182138/download" rel="noreferrer noopener">briefing document</a>, the FDA indicated that combining immune checkpoint inhibitors (ICIs) with standard chemotherapy does not seem to offer benefits for patients with PD-L1 expression below 1%. Patients with PD-L1 levels of 10% or higher experience the most significant benefit.
The advantages remain unclear for those with PD-L1 levels between 1% and 10%, and interpreting the data is difficult.
Given that patients with low or absent PD-L1 expression are unlikely to benefit, administering anti-PD-1 therapy may introduce risks, including severe immune-related adverse effects, which can further diminish the quality of life in individuals already dealing with malignancy.
"Although these results are exploratory &#8230; strong evidence does not appear to support the use of anti-PD-L1 drugs in patients with low PD-L1 expression," the FDA <a target="_blank" href="https://www.fda.gov/media/182143/download" rel="noreferrer noopener">said</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma" target="_blank" rel="noreferrer noopener">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>.</li>
</ul>
Image by PDPics from Pixabay

BGNE

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed new long-term results on Wednesday, showing promise for treatment in patients with <a href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss">moderate-to-severe atopic dermatitis</a>. 
What Happened: The company&#8217;s data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV).
The EADV is a leading professional society focused on the fields of dermatology and venereology.
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a>.
Why It Matters: The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older.
<ul>
<li>84% of the patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin (IGA 0,1) at three years.</li>
<li>87% of the patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.</li>
<li>83% of the patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require high-potency topical corticosteroids or systemic treatments.</li>
</ul>
Those who participated in the study have moderate-to-severe atopic dermatitis (eczema).
The European Union approved Ebglyss in 2023. Japan approved it in January; additional markets are expected to follow suit.
Lilly has exclusive rights for the development and commercialization of Ebglyss in the U.S. and elsewhere outside&nbsp;Europe.
In Europe, Lilly&#8217;s partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.
Price Action: Eli Lilly stock is up 0.17% at $926 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41023437/mercks-experimental-favezelimabkeytruda-combo-fails-in-late-stage-colorectal-cancer-study" target="_blank" rel="noreferrer noopener">Merck&#8217;s Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study</a></li>
</ul>
Image: Shutterstock

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years

On Wednesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41020856/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed-dose-combinati" rel="noreferrer noopener">colorectal cancer (mCRC)</a>.
The US drug giant said the study did not meet its primary endpoint of overall survival.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40926567/mercks-keytruda-secures-first-fda-approval-for-rare-form-aggressive-cancer" rel="noreferrer noopener">Merck&#8217;s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer</a>.
At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not demonstrate an improvement in OS compared to standard of care (regorafenib or TAS-102 [trifluridine and tipiracil hydrochloride]).
The safety profile of the fixed-dose combination was consistent with that observed for favezelimab and pembrolizumab in previously reported studies, with no new safety signals observed.
A full data evaluation is ongoing.
In the U.S., Keytruda is approved for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Keytruda has not been approved for the treatment of MSS mCRC.
Last month, Merck stopped two Keytruda Phase 3 trials, KEYNOTE-867&nbsp;and KEYNOTE-630, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data" rel="noreferrer noopener">after underwhelming data</a>.
Concurrently, on Wednesday, Japan&#8217;s drug regulator approved new indications for Keytruda (pembrolizumab), in certain <a href="https://www.benzinga.com/pressreleases/24/09/b41020647/mercks-keytruda-pembrolizumab-receives-new-approvals-in-japan-for-certain-patients-with-non-small-" target="_blank" rel="noreferrer noopener">lung and urothelial cancers</a>.
<h2 class="wp-block-heading">Merck Stock Prediction For 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Merck &amp; Co have an average 1-year price target of $142.57, representing an expected upside of 24.02%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Merck &amp; Co, while 5 analysts have bullish ratings. The street high price target from Cantor Fitzgerald is $155.0, while the street low from Wells Fargo is $125.0.
Price Action: MRK stock is down 0.10% at $114.85 during the premarket session at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41021010/vertex-energy-files-for-chapter-11-bankruptcy-secures-80m-lifeline-financing" target="_blank" rel="noreferrer noopener">Vertex Energy Files For Chapter 11 Bankruptcy, Secures $80M Lifeline Financing</a>.</li>
</ul>
Photo Courtesy of Merck

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

Merck Says Phase 3 KEYFORM-007 Trial Of Fixed-dose Combination Of Favezelimab And Keytruda (Pembrolizumab) Did Not Meet Its Primary Endpoint Of Overall Survival For Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

<ul>
<li>KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment, for patients with non-small cell lung carcinoma (NSCLC) based on results from the Phase 3 KEYNOTE-671 trial;</li>
<li>KEYTRUDA in combination with Padcev (enfortumab vedotin-ejfv) for the first-line treatment of patients with radically unresectable urothelial carcinoma based on results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in a research collaboration with Pfizer (previously Seagen) and Astellas;</li>
<li>KEYTRUDA monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy based on results from the Phase 2 KEYNOTE-052 trial.</li>
</ul>

The Japanese Ministry Of Health, Labor And Welfare Has Approved New Indications For Merck's Keytruda (Pembrolizumab) In Certain Lung And Urothelial Cancers

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases

Merck Animal Health Announces Expansion Of NOBIVAC NXT Platform With First And Only RNA-Particle Technology Vaccine For Feline Leukemia Virus

Deep-pocketed investors have adopted a bearish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 2 are puts, totaling $84,071, and 9 are calls, amounting to $500,344.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $125.0 for Merck &amp; Co, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 3469.29, with a total volume reaching 7,958.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $110.0 to $125.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727118928_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.74</td>
<td>$1.65</td>
<td>$1.68</td>
<td>$117.00</td>
<td>$120.4K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.77</td>
<td>$2.72</td>
<td>$2.72</td>
<td>$120.00</td>
<td>$98.3K</td>
<td>4.8K</td>
<td>64</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.76</td>
<td>$0.72</td>
<td>$0.75</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>9.8K</td>
<td>998</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.95</td>
<td>$9.85</td>
<td>$9.89</td>
<td>$115.00</td>
<td>$49.4K</td>
<td>298</td>
<td>4</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.0</td>
<td>$2.98</td>
<td>$2.98</td>
<td>$115.00</td>
<td>$45.2K</td>
<td>4.5K</td>
<td>468</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a trading volume of 3,262,924, the price of MRK is down by -1.08%, reaching $115.9.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $155.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $155. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Merck & Co Unusual Options Activity For September 23

On Saturday, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) presented positive trial data for experimental drug designed for patients suffering from&nbsp;cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as&nbsp;9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight.
<h3>Paving The Way For The World&rsquo;s First Treatment For Cancer Cachexia</h3>
The mid-stage trial results showed that patients that were treated with the experimental drug that Pfizer developed showed improvements in body weight, muscle mass, quality of life and physical function. Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically&nbsp;for this condition. This would translate to Pfizer saving many lives as 80% of cancer patients who suffer from this condition are not expected to make it beyond a year of being diagnosed as they are unable to meet their body&rsquo;s energy and nutritional needs. The condition also makes the general treatment of cancer less effective and lowers the odds of survival as it leaves the patient even weaker, unable to tolerate the treatment.&nbsp;
<h3>The Trial</h3>
Involving&nbsp;187 patients diagnosed with non-small cell lung cancer, pancreatic cancer or colorectal cancer and high levels of a key driver of cachexia, patients who took the highest dose of ponsegromab, which is 400 milligrams, over the course of 12 weeks&nbsp;observed a&nbsp;5.6% increase in weight compared to those patients who received a placebo. Patients who took lower doses of 200 or 100-milligrams observed roughly 3.5% and 2% increase in body weight compared to the placebo group. Pfizer added that experts consider weight gain greater than 5% as a &ldquo;clinically meaningful difference&rdquo; when it comes to cancer patients with cachexia and noted that increased appetite and improvement in physical activity is what was most encouraging.&nbsp;&nbsp;The good news is that no significant side effects of the drug were observed. Pfizer is planning to begin late-stage development studies in 2025 that can be used to file for approval, while also studying the effect of ponsegromab in a phase two trial in patients diagnosed with heart failure.
Catching up to Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) and others on the cancer front.
It&rsquo;s no secret that Pfizer has turned to oncology in an effort to combat the Covid-19 decline.&nbsp;&nbsp;To turn its business around, it targeted as many as 8 blockbuster cancer drugs by the end of this decade. One of its main Covid-19 rivals, Moderna is expected to launch its experimental cancer vaccine as early as next year.
Together with Merck &amp; Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>), Moderna is currently testing their combined treatment for advanced melanoma in a large-scale Phase III trial. Approximately, 1,089 patients at more than 165 sites across the globe will be tested to assess the efficiency of the experimental vaccine mRNA-4157 that Moderna and Merck co-developed, along with the immunotherapy drug, Keytruda, that is already a blockbuster for Merck. The study will assess the efficiency of the treatment that Moderna and Merck created in achieving a recurrence-free survival, while the secondary endpoints are distant metastasis-free survival, along with overall survival and safety.
&nbsp;
Codenamed mRNA-4359, Moderna also designed a vaccine to boost people&#39;s immunity to better recognize and fight a variety of advanced solid tumor cancers. During the above-mentioned congress that took place in Barcelona, Spain, on Saturday, researchers at King&rsquo;s College London&nbsp;presented&nbsp;Phase I/II trial to test Moderna&rsquo;s vaccine candidate, more precisely its ability to sensitize the immune system to two specific proteins commonly common in tumor cells as well as other cells that suppress the immune system, PD-L1 and IDO1.&nbsp;From 16 patients diagnosed with advanced lung cancer, melanoma, and other solid tumors who were able to have their responses measured, eight patients showed no signs of their tumors growing and there were no new tumors formed. In addition, tests found that the vaccine seemed to generate a noticeable increase in immune cells that could recognize PD-L1 and IDO1.&nbsp;While more data will be needed to know whether mRNA-4359 can work as hoped, these results are promising.&nbsp;
The future of cancer treatment looks bright.
Besides vaccines designed to help patients combat cancer, Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) advanced on the early screening and prevention front. A molecular genetics diagnostic company specialized in the early detection of cancer,&nbsp;Mainz Biomed is currently seeking FDA approval for its colorectal cancer test, ColoAlert. With an innovative portfolio of mRNA biomarkers, Mainz Biomed is promising to set a new gold standard for noninvasive detection of advanced adenoma, which is a well-known pre-cancerous condition. This week, Mainz Biomed announced its newest Brand Ambassador,&nbsp;Petra Smeltzer Starke, known serving as&nbsp;General Counsel to the White House Council of Economic Advisors and Senior Advisor to President Obama. Ms. Smeltzer Starke&rsquo;s role will be to help to raise awareness on the importance of early detection of colorectal cancer. If diagnosed early, up to 90% of colorectal cancer cases can be treated successfully. Therefore, early screening makes all the difference.&nbsp;
By the looks of it, years ahead seem promising when it comes to revolutionizing cancer treatment.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Eurozone

Pfizer Advances On Its Cancer Journey

The first opinion recommends the approval of KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy.
The second positive opinion recommends the approval of KEYTRUDA in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.
The CHMP&#39;s recommendations will now be reviewed by the European Commission for marketing authorization in the European Union (EU), and final decisions are expected in the&nbsp;fourth quarter&nbsp;of 2024.

Merck Says European Medicines Agency's CHMP Adopted Positive Opinions Recommending Approval Of Keytruda (Pembrolizumab), Its Anti-PD-1 Therapy, For Two Indications In Gynecologic Cancers

Wednesday, the FDA approved Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40915575/fda-approves-mercks-keytruda-pembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line" rel="noreferrer noopener">malignant pleural mesothelioma (MPM).</a>
The approval marks the first indication for Keytruda in MPM in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40896344/merckdaiichi-sankyo-partnered-lung-cancer-candidate-meets-primary-goal-in-late-stage-study" rel="noreferrer noopener">Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study</a>.
MPM&nbsp;is&nbsp;a rare, aggressive cancer that forms in the lining of the lungs and chest.
The approval is based on pivotal Phase 2/3 IND.227/KEYNOTE-483 trial data.
Keytruda plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS), reducing the risk of death by 21% compared to chemotherapy alone.
Median OS was 17.3 months for Keytruda plus chemotherapy versus 16.1 months for chemotherapy alone.
Keytruda plus chemotherapy also significantly improved progression-free survival (PFS) versus chemotherapy alone.
The overall response rate (ORR) was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%), respectively.
Adverse reactions occurring in patients with MPM were generally similar to those in other patients receiving Keytruda in combination with pemetrexed and platinum chemotherapy.
In August, Merck discontinued two Keytruda <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data" rel="noreferrer noopener">late-stage studies</a>.
<ul>
<li>Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy for stage I or II non-small cell lung cancer, including those who are medically inoperable or <a href="https://www.benzinga.com/pressreleases/24/08/b40621006/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials" target="_blank" rel="noreferrer noopener">have refused surgery</a>.</li>
<li>Phase 3 KEYNOTE-630 trial of Keytruda for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent DMC.</li>
</ul>
Price Action: MRK stock is trading 0.04% higher at $118.34&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/09/40919923/consumer-giant-reckitt-seeks-help-from-investment-banks-to-evaluate-options-for-homecare-brands-baby" target="_blank" rel="noreferrer noopener">Consumer Giant Reckitt Seeks Help From Investment Banks To Evaluate Options For Homecare Brands, Baby Formula</a>.</li>
</ul>

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

U.S. port strike expected to have limited impact on healthcare supply chain: HHS

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read more… The growing number of elderly people worldwide is fueling a surge in demand for healthcare services, pharmaceuticals, and insurance, giving the healthcare sector a significant tailwind. Additionally, with technological advancements and innovative treatments on the rise, the future of the industry looks brighter than ever.
Amid this backdrop, investors looking to invest in the healthcare sector could keep an eye on fundamentally strong companies like Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), which are well-positioned to capitalize on this demographic shift.
According to a report, one in five Americans will be 65 or older by 2040, reaching a <a href="https://www.urban.org/policy-centers/cross-center-initiatives/program-retirement-policy/projects/data-warehouse/what-future-holds/us-population-aging">total of 80 million</a>. As the global population ages, the need for biopharma products and modern, effective drugs to manage long-term diseases is poised to increase more than ever. The pharmaceuticals market is forecasted to generate $1.45 trillion in revenue by 2029, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">exhibiting a CAGR of 4.7%</a>.
Additionally, the health insurance sector, particularly those offering Medicare-related products and services, is poised to capitalize on this trend. As per Precedence Research, the global health insurance market is anticipated to hit $5.12 trillion by 2034, growing at a <a href="https://precedenceresearch.com/health-insurance-market">CAGR of 7.4%</a>.
Considering these conducive trends, let's look at the fundamentals of the above-mentioned stocks in detail:
Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>)
LLY is a medicine company that discovers, develops, manufactures, and markets human pharmaceuticals worldwide. The company offers medicines for diabetes, obesity, rheumatoid arthritis, plaque psoriasis, ulcerative colitis, depressive disorder, and others, in addition to oncology products.
On September 24, LLY announced that the Ministry of Health, Labour and Welfare of Japan approved Kisunla for treating adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) and those with mild dementia stage of AD. This treatment will help reduce the infusion burden for eligible patients.  
On September 13, LLY received approval from the U.S. Food and Drug Administration (FDA) for EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor. This biologic treatment is intended for adults and children aged 12 years and above with moderate-to-severe atopic dermatitis that is not well controlled with topical therapies. It aims to provide long-lasting efficacy to patients with a maintenance dose administered once a month for a year.
For the second quarter (ended June 30, 2024), LLY reported revenue of $11.30 billion, representing a 36% growth from the prior-year quarter. It reported a non-GAAP gross profit of $9.27 billion, indicating a 39.8% growth from the prior year quarter with a margin of 80.8% (up 250 bps year-over-year).
In addition, its operating income increased 74.8% year-over-year to $3.71 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $3.54 billion and $3.92 per share, up 85.9% and 85.8% year-over-year, respectively.
The company has updated its fiscal year 2024 guidance, increasing its revenue projection by $3 billion to a range of $45.40 billion to $46.60 billion. LLY's EPS is anticipated to fall between $15.10 and $15.60. On a consolidated adjusted basis, its non-GAAP EPS is expected to range from $16.10 to $16.60.
Street expects LLY's revenue for the fiscal third quarter (ending September 2024) to increase 26.5% year-over-year to $12.01 billion. Its EPS for the current quarter is expected to improve substantially from the year-ago value to $4.50. Moreover, it beat the EPS estimates in each of the trailing four quarters, which is promising.
Shares of LLY have surged 65.3% over the past year and 59.3% over the past nine months to close the last trading session at $909.32.
LLY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LLY has an A grade for Sentiment and a B for Growth. It is ranked #37 out of 157 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to see the additional ratings for LLY (Value, Momentum, Stability, and Quality).
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified health care company. The company operates through four segments: UnitedHealthcare; Optum Health; Optum Insight; and Optum Rx.
On September 17, the UNH Community Plan of New Mexico announced a collaboration with the school-based healthcare provider Goodside Health to provide and expand integrated physical and behavioral healthcare services to 50 New Mexico schools, with an investment of $250,000. This collaboration will help school children gain healthier access to primary care as well as mental health care.
On August 29, UNH announced a three-year strategic partnership with Goodwill Industries International, involving a $4.5 million investment, to increase access to education and training, support health-related social needs, and create workforce development opportunities. This partnership aims to help people overcome barriers that prevent them from obtaining employment and to create opportunities for job seekers.
In the fiscal second quarter that ended on June 30, 2024, UNH's total revenue increased 6.4% year-over-year to $98.86 billion. The company's adjusted net earnings came in at $6.31 billion, up 9.3% year-over-year, while its adjusted EPS grew 10.7% from the year-ago value to $6.80.
According to the financial guidance for fiscal year 2024, the company's adjusted earnings per share is anticipated to range from $27.50 to $28.
The consensus revenue estimate of $99.28 billion for the fiscal third quarter (ending September 2024) represents a 7.5% increase year-over-year. The consensus EPS estimate of $7.06 for the same quarter indicates a 7.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has surged 18.8% over the past three months to close the last trading session at $574.81.
UNH's mixed fundamentals are reflected in its POWR Ratings. The stock has a B grade for Stability and Sentiment. It is ranked #5 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
Beyond what is stated above, we've also rated UNH for Growth, Value, Momentum, and Quality. Get all UNH's ratings <a href="https://stocknews.com/stock/UNH/">here</a>.
Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global health care company offering health solutions through its prescription medicines, including biological therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On September 25, MRK received new approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for KEYTRUDA's significant role as a combination therapy and as a monotherapy for certain patients with urothelial carcinoma.
On September 18, MRK announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA in combination with pemetrexed and platinum chemotherapy as a first-line treatment option for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
MRK's sales for the second quarter ended June 30, 2024, increased 7.2% year-over-year to $16.11 billion, while its KEYTRUDA product sales improved by 15.9% from the year-ago value to $7.27 billion. The company's non-GAAP net income stood at $5.81 billion compared to the prior-year quarter's loss of $5.22 billion, while its non-GAAP EPS came in at $2.28 versus a loss of $2.06 per share last year.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.40 billion to $64.40 billion, an increase from the previous guidance of $63.10 billion to $64.30 billion. The company also expects non-GAAP EPS to be between $7.94 and $8.04.
Analysts expect MRK's revenue for the fourth quarter (ending December 2024) to increase 7.1% year-over-year to $15.67 billion, while its EPS for the same period is expected to grow significantly from the prior year to $1.91. Moreover, the company topped the consensus revenue estimates in each of the trailing four quarters.
Over the past year, the stock has gained 7.3%, closing the last trading session at $113.09.
MRK's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Value and Stability. Within the Medical - Pharmaceuticals industry, it is ranked #7 out of 157 stocks. <a href="https://stocknews.com/stock/MRK/">Click here</a> to see MRK's ratings for Growth, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $884.11 per share on Friday morning, down $25.21 (-2.77%). Year-to-date, LLY has gained 52.41%, versus a 21.84% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lly-unh-mrk-3-healthcare-stocks-to-watch-as-the-aging-population-drives/>3 Healthcare Stocks to Watch as the Aging Population Drives Demand</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

Gritstone downgraded by Jones, B. Riley over cancer vaccine data

U.S. tweaks 2025 Medicare price negotiation process

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Wells Fargo's 'Core' stocks: GOOGL, HD, KO, and more

EU regulators reviewing safety of finasteride, dutasteride

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Buy 2 October Dogs Of The Dow And Watch 5 More

AAPL

ABSI

ABUS

ALPMF

ALPMY

AMZN

ANTX

ATHA

AVGO

AZNCF

BAYRY

BAYZF

BBIO

BMRN

CDTX

CMCSA

CRBU

CSCO

CVAC

FGEN

GLYC

GOOGL

GRTS

HLVX

IBRX

INAB

LSTR

LXRX

MSFT

NVDA

ORCL

PAYX

PGEN

QURE

RAPT

RHHBF

RHHBY

RHHVF

RLAY

RPTX

SBUX

SLRN

SNYNF

TEVA

TEVJF

VIRX

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

Merck's KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Comments

Merck & Co

매도 수량

Merck & Co (NYSE:MRK) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌